MRTX - Mirati Therapeutics, Inc.
| Previous Close | 70.57 |
| Open | 69.69 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1100 |
| Day's Range | 69.69 - 74.53 |
| 52 Week Range | 28.50 - 80.00 |
| Volume | 1,255,015 |
| Avg. Volume | 658,546 |
| Market Cap | 2.664B |
| Beta (3Y Monthly) | 2.61 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.84 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 81.46 |
- Investor's Business Daily•3 days ago
Here Are The Biotech Winners Ahead Of 2019's Biggest Cancer Meeting
Biotech companies Iovance Biotherapeutics, MacroGenics and Mirati Therapeutics were among the winners in a slew of data for cancer treatments released late Wednesday. Stocks rose Thursday.
- Motley Fool•3 days ago
Here's Why Mirati Therapeutics Is Surging Today
Lackluster results from Amgen's KRAS inhibitor program are clearing a path for Mirati's candidate.
- Benzinga•4 days ago
What's Triggering The Rise In Mirati Shares?
Mirati Therapeutics, Inc. (NASDAQ: MRTX ) shares were rallying by about 15 percent Thursday as traders circulated word that drugmaker Amgen, Inc. (NASDAQ: AMGN ) KRAS G12C inhibitor abstract showed promising ...
- Zacks•6 days ago
Options Traders Expect Huge Moves in Mirati Therapeutics (MRTX) Stock
Investors need to pay close attention to Mirati Therapeutics (MRTX) stock based on the movements in the options market lately.
- Simply Wall St.•13 days ago
What You Must Know About Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) Beta Value
Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! If you own shares in Mirati Therapeutics, Inc. (NASDAQ:MRTX) then it's worth thinking about how it co...
- Associated Press•20 days ago
Mirati: 1Q Earnings Snapshot
The San Diego-based company said it had a loss of $1.17 per share. The results did not meet Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for ...
- PR Newswire•20 days ago
Mirati Therapeutics Reports First Quarter 2019 Financial Results
SAN DIEGO , April 29, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the first quarter ended March 31, 2019 ...
- Insider Monkey•20 days ago
Were Hedge Funds Right About Flocking Into Mirati Therapeutics, Inc. (MRTX) ?
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
- PR Newswire•2 months ago
Mirati Therapeutics To Present At The H.C. Wainwright & Co. Global Life Sciences Conference
SAN DIEGO , April 1, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at the H.C. Wainwright & Co. Global Life Sciences Conference ...
- Simply Wall St.•2 months ago
The Mirati Therapeutics (NASDAQ:MRTX) Share Price Has Gained 287%, So Why Not Pay It Some Attention?
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! When you buy a stock there is always a possibilityRead More...
- PR Newswire•2 months ago
Mirati Therapeutics To Present At Upcoming Healthcare Conferences
SAN DIEGO , March 5, 2019 Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical stage targeted oncology company, will present at two upcoming healthcare conferences. Cowen 39 th Annual Healthcare Conference ...
- PR Newswire•3 months ago
Mirati Therapeutics Reports Fourth Quarter Financial Results
SAN DIEGO , Feb. 28, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the fourth quarter and full-year ended ...
- GlobeNewswire•3 months ago
Analysis: Positioning to Benefit within Biogen, Mirati Therapeutics, PLDT, Zebra Technologies, Domino's Pizza, and Solar Capital — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Feb. 25, 2019 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- PR Newswire•3 months ago
Mirati Therapeutics Announces The Appointment Of Faheem Hasnain As Chairman Of The Board Of Directors
SAN DIEGO, Feb. 19, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology company, today announced the appointment of Faheem Hasnain as Chairman of the Board, effective February 15, 2019. Dr. Rodney Lappe Ph.D. is retiring from the board and his role as Chairman and will not seek re-election at the Company's 2019 annual meeting of shareholders. Dr. Lappe has provided leadership and guidance to the Company over the last eight years and has served with distinction as Chair for the last five years.
- PR Newswire•3 months ago
Mirati Therapeutics To Present At The Guggenheim Healthcare Talks Idea Forum & Oncology Day
SAN DIEGO , Feb. 7, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the Guggenheim Healthcare Talks Idea Forum & Oncology ...
- Motley Fool•3 months ago
Here's Why Mirati Therapeutics Jumped 55.8% in January
Investors cheered the biotech's plans to move its lead candidate forward.
- ACCESSWIRE•4 months ago
Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics
NEW YORK, NY / ACCESSWIRE / January 31, 2019 / U.S. equities regained footing on Wednesday as investors cheered the latest round of corporate earnings and the Federal Reserve kept the interest rates unchanged ...
- Simply Wall St.•4 months ago
How Many Insiders Sold Mirati Therapeutics, Inc. (NASDAQ:MRTX) Shares?
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. The flip side of that is that there are more Read More...
- Benzinga•4 months ago
The Daily Biotech Pulse: PTC Therapeutics, Select Biosciences Offering, Unity Biotech Expands Early-Stage Osteoarthritis Drug Study
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 22) Veracyte Inc (NASDAQ: VCYT ) Down In The Dumps (Biotech ...
- PR Newswire•4 months ago
Mirati Therapeutics Announces Closing Of Public Offering Of Common Stock And Full Exercise Of Underwriters' Option To Purchase Additional Shares
SAN DIEGO , Jan. 22, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (Nasdaq: MRTX) today announced the closing of its previously announced underwritten public offering of 1,854,838 shares of its common ...
- Benzinga•4 months ago
The Daily Biotech Pulse: FDA Panel Backs Amgen's Hypertension Drug, Adamis Allergy Drug Launched In US
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peak (Biotech stocks hitting 52-week highs on Jan. 16) Avenue Therapeutics Inc (NASDAQ: ATXI ) BioDelivery ...
- PR Newswire•4 months ago
Mirati Therapeutics Announces Pricing Of Public Offering Of Common Stock
SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced the pricing of an underwritten public offering of 1,612,903 shares of its common stock at a price to the public of $62.00 per share. The aggregate gross proceeds from this offering are expected to be approximately $100.0 million, before deducting underwriting discounts and commissions and estimated offering expenses payable by Mirati. Mirati has also granted the underwriters a 30-day option to purchase up to an additional 241,935 shares of common stock in connection with the public offering.
- PR Newswire•4 months ago
Mirati Therapeutics Announces Proposed Public Offering Of Common Stock
SAN DIEGO, Jan. 16, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX) today announced that it intends to offer and sell, subject to market and other conditions, $75.0 million of shares of its common stock in an underwritten public offering. Mirati expects to grant the underwriters a 30-day option to purchase up to an additional $11.25 million of shares of its common stock. All of the shares are being offered by Mirati.
- PR Newswire•4 months ago
Mirati Therapeutics Announces Dosing Of First Patient In Phase 1/2 Clinical Trial Of MRTX849, A Novel KRAS G12C Inhibitor
SAN DIEGO, Jan. 15, 2019 /PRNewswire/ -- Mirati Therapeutics, Inc. (MRTX), a clinical stage targeted oncology company, announced today that it has dosed the first patient in a Phase 1/2 clinical trial of MRTX849, an investigational KRAS G12C inhibitor for patients with advanced solid tumors that harbor KRAS G12C mutations. "Today we have achieved an important milestone in the battle against cancers driven by KRAS mutations, one of the most common and difficult to treat patient populations. MRTX849 has been designed to specifically target KRAS G12C mutations, which are thought to be responsible for at least 14% of non-small cell lung adenocarcinoma, 4% of colorectal cancer, and subsets of other types of cancers," said Charles Baum, M.D., Ph.D., President and Chief Executive Officer of Mirati.
- ACCESSWIRE•4 months ago
Today's Research Reports on Trending Tickers: Aimmune Therapeutics and Mirati Therapeutics
NEW YORK, NY / ACCESSWIRE / January 15, 2019 / Wall Street extended losses on Monday as concerns of a global economic slowdown were reignited on weaker-than-expected economic data from China. In December, ...
